These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 5481776)

  • 1. Stimulation of human-growth-hormone secretion by L-dopa.
    Boyd AE; Lebovitz HE; Pfeiffer JB
    N Engl J Med; 1970 Dec; 283(26):1425-9. PubMed ID: 5481776
    [No Abstract]   [Full Text] [Related]  

  • 2. Amantadine enhancement of L-DOPA induced growth hormone stimulation.
    Massara F; Camanni F; Molinatti GM
    Horm Metab Res; 1973 Nov; 5(6):454-6. PubMed ID: 4767002
    [No Abstract]   [Full Text] [Related]  

  • 3. Effect of intravenous infusion of L-DOPA on plasma growth hormone levels in man.
    Imura H; Nakai Y; Matsukura S; Matsuyama H
    Horm Metab Res; 1973 Jan; 5(1):41-5. PubMed ID: 4706921
    [No Abstract]   [Full Text] [Related]  

  • 4. Dissociation of growth hormone and prolactin secretion in Parkinson's disease following chronic L-dopa therapy.
    Malarkey WB; Cyrus J; Paulson GW
    J Clin Endocrinol Metab; 1974 Aug; 39(2):229-35. PubMed ID: 4371345
    [No Abstract]   [Full Text] [Related]  

  • 5. Effects of L-dopa on plasma growth hormones and insulin.
    Kytomaki O; Nousiainen R; Pekkarinen A; Rinne U; Siirtola T; Sonninen V; Viljanen M
    Acta Neurol Scand Suppl; 1972; 51():125-6. PubMed ID: 4514338
    [No Abstract]   [Full Text] [Related]  

  • 6. [Effect of L-dopa on pituitary TSH and GH secretion in Parkinson's disease].
    Sakoda M; Kusaka T; Baba S; Shirakata S
    Nihon Naibunpi Gakkai Zasshi; 1972 Jul; 48(4):241-4. PubMed ID: 5066290
    [No Abstract]   [Full Text] [Related]  

  • 7. The effect of L-dopa on plasma growth hormone, insulin, and thyroxine.
    Kansal PC; Buse J; Talbert OR; Buse MG
    J Clin Endocrinol Metab; 1972 Jan; 34(1):99-105. PubMed ID: 5061778
    [No Abstract]   [Full Text] [Related]  

  • 8. Metabolic responses to acute and chronic L-dopa administration in patients with parkinsonism.
    Sirtori CR; Bolme P; Azarnoff DL
    N Engl J Med; 1972 Oct; 287(15):729-33. PubMed ID: 5056733
    [No Abstract]   [Full Text] [Related]  

  • 9. Effect of L-dopa administration on growth hormone secretion in normal subjects and Parkinsonian patients.
    Cavagnini F; Peracchi M; Scotti G; Raggi U; Pontiroli AE; Bana R
    J Endocrinol; 1972 Sep; 54(3):425-33. PubMed ID: 5071365
    [No Abstract]   [Full Text] [Related]  

  • 10. [Dopaminergic control of the diencephalo-pituitary axis for somatotropin secretion].
    Cavagnini F; Pontiroli AE; Raggi U; Peracchi M; Malinverni A
    Folia Endocrinol; 1973 Dec; 26(6):483-9. PubMed ID: 4801258
    [No Abstract]   [Full Text] [Related]  

  • 11. [Effect of L-dopa on pituitary hormones and on carbohydrate and fat metabolism in normal persons and in patients with Parkinsonism].
    Geser CA; Müller-Hess R; Dufresne JJ; Felber JP; Vannotti A
    Schweiz Med Wochenschr; 1973 May; 103(19):690-7. PubMed ID: 4703913
    [No Abstract]   [Full Text] [Related]  

  • 12. Release of human growth hormone, follicle stimulating hormone, and luteinizing hormone in response to L-dihydroxy-phenylalanine (L-dopa) in normal man.
    Perlow MJ; Sassin JF; Boyar R; Hellman L; Weitzman ED
    Dis Nerv Syst; 1972 Dec; 33(12):804-10. PubMed ID: 4668972
    [No Abstract]   [Full Text] [Related]  

  • 13. [Serum gonadotropic level under the medication L-dopa].
    Janzik HH; Heller S
    Arzneimittelforschung; 1974 Aug; 24(8):1084-5. PubMed ID: 4479602
    [No Abstract]   [Full Text] [Related]  

  • 14. [Clinical effect of L-DOPA and electromyographic study of Parkinsonism].
    Sato G; Ito H; Handa Y; Takahashi I; Iijima K
    No To Shinkei; 1971 Mar; 23(3):325-32. PubMed ID: 5107821
    [No Abstract]   [Full Text] [Related]  

  • 15. [Growth hormone stimulation with L. Dopa].
    Elkaïm R; Halimi S; Guidicelli C; Agnius-Delord C; Hadjian A; Perret J; Micoud M
    Nouv Presse Med; 1972 Mar; 1(10):675-7. PubMed ID: 4553974
    [No Abstract]   [Full Text] [Related]  

  • 16. Improvement in mono-manual dexterity in parkinsonism when supplementing levodopa with an extracerebral decarboxylase inhibitor, RO 4-4602.
    Knutsson E; Mårtensson A
    Scand J Rehabil Med; 1974; 6(2):89-93. PubMed ID: 4837060
    [No Abstract]   [Full Text] [Related]  

  • 17. Effect of L-dopa on plasma free fatty acids and plasma glucose.
    Rivera-Calimlim L; Bianchine JR
    Metabolism; 1972 Jul; 21(7):611-7. PubMed ID: 5040916
    [No Abstract]   [Full Text] [Related]  

  • 18. Glucose-suppressible growth hormone release after L-dopa administration to normal subjects.
    Johansen K
    Metabolism; 1973 Jun; 22(6):773-8. PubMed ID: 4709329
    [No Abstract]   [Full Text] [Related]  

  • 19. L-DOPA and pituitary hormone secretion.
    Hayek A; Crawford JD
    J Clin Endocrinol Metab; 1972 May; 34(5):764-6. PubMed ID: 5012491
    [No Abstract]   [Full Text] [Related]  

  • 20. [10 years of L-DOPA therapy of Parkinson's syndrome].
    Birkmayer W
    Wien Klin Wochenschr; 1971 Apr; 83(13):221-7. PubMed ID: 4254333
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.